Hence, the developed insulin chitosan-coated transfersomes proved to lead to increased brain drug delivery through the intranasal route, with decreased systemic distribution and good neuroregeneration capability, making them a promising alternative for future Alzheimer’s disease treatments. This evidence concerns the gene INS and Alzheimer disease.